Silence Therapeutics plc Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019
Silence Therapeutics plc (SLN) reported Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 of 374.49 GBP/shares for the 12-month period ending 2023-12-31, per its 20-F filed 2024-03-13.
Discontinued › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019 · last filed 2024-03-13
GBP/shares
| Period end | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 12 month | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 12 month as first filed |
|---|---|---|
| 2023-12-31 | 374.49 GBP/shares 20-F · filed 2024-03-13 | |
| 2022-12-31 | 1.84K GBP/shares 20-F · filed 2024-03-13 | |
| 2021-12-31 | 554.60 GBP/shares 20-F · filed 2024-03-13 | |
| 2020-12-31 | 351.90 GBP/shares 20-F · filed 2023-03-15 | 3.52 GBP/shares 20-F/A · filed 2021-04-29 |
| 2019-12-31 | 129.40 GBP/shares 20-F · filed 2022-03-17 | 1.29 GBP/shares 20-F/A · filed 2021-04-29 |
| 2018-12-31 | 0.00 GBP/shares 20-F/A · filed 2021-04-29 |
USD/shares
| Period end | Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement2019 12 month |
|---|---|
| 2023-12-31 | $14.01 20-F · filed 2024-03-13 |
| 2022-12-31 | $22.30 20-F · filed 2024-03-13 |